Brian Jackson Wentworth

Dr. Brian Jackson Wentworth

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
BWBrian Jackson Wentworth
Brian Jackson Wentworth
Helmy M. SiragyHelmy M. Siragy
Helmy M. Siragy
Hypothalamus-pituitary-adrenal axis assessment in patients with cirrhosis is challenging. The phenotype of fatigue, hypotension, electrolyte disarray, and abdominal pain characterizing primary adrenal insufficiency (AI) overlaps significantly with decompensated liver disease. Reliance on total cortisol assays in hypoproteinemic states is problematic, yet abnormal stimulated levels in cirrhosis are associated with poor clinical outcomes. Alternative measures including free plasma or salivary cortisol levels have theoretical merit but are limited by unclear prognostic significance and undefined cirrhosis-specific reference ranges. Further complicating matters is that AI in cirrhosis represents a spectrum of impairment. Although absolute cortisol deficiency can occur, this represents a minority of cases. Instead, there is an emerging concept that cirrhosis, with or without critical illness, may induce a “relative” cortisol deficiency during times of stress. In addition, the limitations posed by decreased synthesis of binding globulins in cirrhosis necessitate re-evaluation of traditional AI diagnostic thresholds.

Verified
Journal Article
Open access
PDF file
MMMary McGrath
Mary McGrath
BWBrian Jackson Wentworth
Brian Jackson Wentworth
The renin–angiotensin system (RAS) is a complex homeostatic entity with multiorgan systemic and local effects. Traditionally, RAS works in conjunction with the kidney to control effective arterial circulation, systemic vascular resistance, and electrolyte balance. However, chronic hepatic injury and resulting splanchnic dilation may disrupt this delicate balance. The role of RAS in liver disease, however, is even more extensive, modulating hepatic fibrosis and portal hypertension. Recognition of an alternative RAS pathway in the past few decades has changed our understanding of RAS in liver disease, and the concept of opposing vs. “rebalanced” forces is an ongoing focus of research. Whether RAS inhibition is beneficial in patients with chronic liver disease appears to be context-dependent, but further study is needed to optimize clinical management and reduce organ-specific morbidity and mortality. This review presents the current understanding of RAS in liver disease, acknowledges areas of uncertainty, and describes potential areas of future investigation.

24 May 2021 in Liver International
Verified
Journal Article
Closed access
PDF file
BWBrian Jackson Wentworth
Brian Jackson Wentworth
RHRebecca M. Haug
Rebecca M. Haug
PNPatrick G. Northup
Patrick G. Northup
SCStephen H. Caldwell
Stephen H. Caldwell
ZHZachary H. Henry
Zachary H. Henry

21 November 2022 in Liver International
Verified
Journal Article
Open access
BWBrian Jackson Wentworth
Brian Jackson Wentworth
MSMatthew Schliep
Matthew Schliep
WNWendy Novicoff
Wendy Novicoff
Helmy M. SiragyHelmy M. Siragy
Helmy M. Siragy
CGCalvin X. Geng
Calvin X. Geng
ZHZachary H. Henry
Zachary H. Henry
Background & Aims: Characterization of relative adrenal insufficiency (RAI) in cirrhosis is heterogeneous with regard to studied patient populations and diagnostic methodology. We aimed to describe the prevalence and prognostic importance of RAI in non‐critically ill patients with cirrhosis.Methods: A systematic review and meta‐analysis was performed using MeSH terms and Boolean operators to search five large databases (Ovid‐MEDLINE, ScienceDirect, Web of Science, Cochrane Library and ClinicalTrials.gov). The population of interest was patients with cirrhosis and without critical illness. The primary outcome was the pooled prevalence of RAI as defined by a peak total cortisol level <18 μg/dl, delta total cortisol <9 μg/dl or composite of the two thresholds in response either a standard‐dose or low‐dose short synacthen test. Odds ratios and standardized mean differences from random‐effects models estimated important clinical outcomes and patient characteristics by adrenal functional status.Results: Twenty‐two studies were included in final analysis, comprising 1991 patients with cirrhosis. The pooled prevalence of RAI was 37% (95% CI 33–42%). The prevalence of RAI varied by Child–Pugh classification, type of stimulation test used, specific diagnostic threshold and by severity of illness. Ninety‐day mortality was significantly higher in patients with RAI (OR 2.88, 95% CI 1.69–4.92, I2 = 15%, p < 0.001).Conclusions: Relative adrenal insufficiency is highly prevalent in non‐critically ill patients with cirrhosis and associated with increased mortality. Despite the proposed multifactorial pathogenesis, no studies to date have investigated therapeutic interventions in this specific population.

12 August 2022 in American Journal of Gastroenterology
Verified
Journal Article
Open access
BWBrian Jackson Wentworth
Brian Jackson Wentworth
ZHZachary H. Henry
Zachary H. Henry
HSHelmy M. Siragy
Helmy M. Siragy

26 December 2024 in Metabolism and Target Organ Damage
Verified
Journal Article
Open access
PDF file
BWBrian Jackson Wentworth
Brian Jackson Wentworth
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in global prevalence and becoming a leading indication for liver transplantation (LT). The management of MASLD has been well-studied in the pre-LT setting, and we are entering into a golden era of pharmacologic options designed to resolve steatohepatitis and reverse fibrosis. However, the implications of MASLD on organ allocation, risk of post-LT recurrence, and optimal post-LT management remain topics of ongoing investigation. One such unique challenge is the growing necessity to use steatotic organs to address the shortage of available organs for all waitlisted patients, while ensuring acceptable outcomes through careful case selection. Additionally, how best to screen, diagnose, and manage post-LT graft steatosis remains an ongoing topic of debate, given the high rates of recurrence or de novo occurrence in patients transplanted for non-MASLD-related etiologies of liver disease. This comprehensive review explores the impact of MASLD across the disease continuum, given it is a chronic illness with a complex pathophysiology and is influenced by other comorbidities and certain medications.